These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

115 related articles for article (PubMed ID: 23069858)

  • 1. Impact of ABCC2 polymorphisms on high-dose methotrexate pharmacokinetics in patients with lymphoid malignancy.
    Simon N; Marsot A; Villard E; Choquet S; Khe HX; Zahr N; Lechat P; Leblond V; Hulot JS
    Pharmacogenomics J; 2013 Dec; 13(6):507-13. PubMed ID: 23069858
    [TBL] [Abstract][Full Text] [Related]  

  • 2. High-dose methotrexate in pediatric acute lymphoblastic leukemia: impact of ABCC2 polymorphisms on plasma concentrations.
    Rau T; Erney B; Göres R; Eschenhagen T; Beck J; Langer T
    Clin Pharmacol Ther; 2006 Nov; 80(5):468-76. PubMed ID: 17112803
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Association of ABCC2 -24C>T polymorphism with high-dose methotrexate plasma concentrations and toxicities in childhood acute lymphoblastic leukemia.
    Liu Y; Yin Y; Sheng Q; Lu X; Wang F; Lin Z; Tian H; Xu A; Zhang J
    PLoS One; 2014; 9(1):e82681. PubMed ID: 24404132
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Urinary coproporphyrin I/(I + III) ratio as a surrogate for MRP2 or other transporter activities involved in methotrexate clearance.
    Benz-de Bretagne I; Zahr N; Le Gouge A; Hulot JS; Houillier C; Hoang-Xuan K; Gyan E; Lissandre S; Choquet S; Le Guellec C
    Br J Clin Pharmacol; 2014 Aug; 78(2):329-42. PubMed ID: 24433481
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Impact of abcc2 [multidrug resistance-associated protein (MRP) 2], abcc3 (MRP3), and abcg2 (breast cancer resistance protein) on the oral pharmacokinetics of methotrexate and its main metabolite 7-hydroxymethotrexate.
    Vlaming ML; van Esch A; van de Steeg E; Pala Z; Wagenaar E; van Tellingen O; Schinkel AH
    Drug Metab Dispos; 2011 Aug; 39(8):1338-44. PubMed ID: 21566011
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Abcc2 (Mrp2), Abcc3 (Mrp3), and Abcg2 (Bcrp1) are the main determinants for rapid elimination of methotrexate and its toxic metabolite 7-hydroxymethotrexate in vivo.
    Vlaming ML; van Esch A; Pala Z; Wagenaar E; van de Wetering K; van Tellingen O; Schinkel AH
    Mol Cancer Ther; 2009 Dec; 8(12):3350-9. PubMed ID: 19996279
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Genetic polymorphisms in candidate genes predict increased toxicity with methotrexate therapy in Lebanese children with acute lymphoblastic leukemia.
    Zgheib NK; Akra-Ismail M; Aridi C; Mahfouz R; Abboud MR; Solh H; Muwakkit SA
    Pharmacogenet Genomics; 2014 Aug; 24(8):387-96. PubMed ID: 25007187
    [TBL] [Abstract][Full Text] [Related]  

  • 8. A mutation in the drug transporter gene ABCC2 associated with impaired methotrexate elimination.
    Hulot JS; Villard E; Maguy A; Morel V; Mir L; Tostivint I; William-Faltaos D; Fernandez C; Hatem S; Deray G; Komajda M; Leblond V; Lechat P
    Pharmacogenet Genomics; 2005 May; 15(5):277-85. PubMed ID: 15864128
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Functionally overlapping roles of Abcg2 (Bcrp1) and Abcc2 (Mrp2) in the elimination of methotrexate and its main toxic metabolite 7-hydroxymethotrexate in vivo.
    Vlaming ML; Pala Z; van Esch A; Wagenaar E; de Waart DR; van de Wetering K; van der Kruijssen CM; Oude Elferink RP; van Tellingen O; Schinkel AH
    Clin Cancer Res; 2009 May; 15(9):3084-93. PubMed ID: 19383815
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Pharmacogenetic analysis of high-dose methotrexate treatment in children with osteosarcoma.
    Hegyi M; Arany A; Semsei AF; Csordas K; Eipel O; Gezsi A; Kutszegi N; Csoka M; Muller J; Erdelyi DJ; Antal P; Szalai C; Kovacs GT
    Oncotarget; 2017 Feb; 8(6):9388-9398. PubMed ID: 27566582
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Early recognition of patients with decreased methotrexate clearance following high-dose methotrexate infusion therapy.
    Ikeda H; Kihira K; Kuwata N; Arai S; Kimura Y; Miyake K; Kitaura T; Fujimura K; Kuramoto A; Fukuchi H
    Hiroshima J Med Sci; 1996 Jun; 45(2):57-62. PubMed ID: 8810132
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Determinants of the elimination of methotrexate and 7-hydroxy-methotrexate following high-dose infusional therapy to cancer patients.
    Joerger M; Huitema AD; van den Bongard HJ; Baas P; Schornagel JH; Schellens JH; Beijnen JH
    Br J Clin Pharmacol; 2006 Jul; 62(1):71-80. PubMed ID: 16842380
    [TBL] [Abstract][Full Text] [Related]  

  • 13. A Time-Dependent Model Describes Methotrexate Elimination and Supports Dynamic Modification of MRP2/ABCC2 Activity.
    Woillard JB; Debord J; Benz-de-Bretagne I; Saint-Marcoux F; Turlure P; Girault S; Abraham J; Choquet S; Marquet P; Barin-Le Guellec C
    Ther Drug Monit; 2017 Apr; 39(2):145-156. PubMed ID: 28196047
    [TBL] [Abstract][Full Text] [Related]  

  • 14. The prognostic value of serum methotrexate area under curve in elderly primary CNS lymphoma patients.
    Kasenda B; Rehberg M; Thürmann P; Franzem M; Veelken H; Fritsch K; Schorb E; Finke J; Lebiedz D; Illerhaus G
    Ann Hematol; 2012 Aug; 91(8):1257-64. PubMed ID: 22456893
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Influence of genetic polymorphisms on intestinal expression and rifampicin-type induction of ABCC2 and on bioavailability of talinolol.
    Haenisch S; May K; Wegner D; Caliebe A; Cascorbi I; Siegmund W
    Pharmacogenet Genomics; 2008 Apr; 18(4):357-65. PubMed ID: 18334920
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Association of
    Razali RH; Noorizhab MNF; Jamari H; James RJ; Teh KH; Ibrahim HM; Teh LK; Salleh MZ
    Pediatr Hematol Oncol; 2020 Apr; 37(3):185-197. PubMed ID: 31870219
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Impact of Abcc2 (Mrp2) and Abcc3 (Mrp3) on the in vivo elimination of methotrexate and its main toxic metabolite 7-hydroxymethotrexate.
    Vlaming ML; Pala Z; van Esch A; Wagenaar E; van Tellingen O; de Waart DR; Oude Elferink RP; van de Wetering K; Schinkel AH
    Clin Cancer Res; 2008 Dec; 14(24):8152-60. PubMed ID: 19088030
    [TBL] [Abstract][Full Text] [Related]  

  • 18. High dose methotrexate population pharmacokinetics and Bayesian estimation in patients with lymphoid malignancy.
    Min Y; Qiang F; Peng L; Zhu Z
    Biopharm Drug Dispos; 2009 Nov; 30(8):437-47. PubMed ID: 19746402
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Population pharmacokinetic study of methotrexate in patients with lymphoid malignancy.
    Faltaos DW; Hulot JS; Urien S; Morel V; Kaloshi G; Fernandez C; Xuan kH; Leblond V; Lechat P
    Cancer Chemother Pharmacol; 2006 Nov; 58(5):626-33. PubMed ID: 16528531
    [TBL] [Abstract][Full Text] [Related]  

  • 20. The pharmacokinetics of high-dose methotrexate in people living with HIV on antiretroviral therapy.
    Dalla Pria A; Bendle M; Ramaswami R; Boffito M; Bower M
    Cancer Chemother Pharmacol; 2016 Mar; 77(3):653-7. PubMed ID: 26696583
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 6.